Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2023 Earnings Conference Call March 18, 2024 8:00 AM ET Company Participants Robert Shawah - CFO David Luci - President and CEO Robert DeLuccia - Executive Chairman Conference Call Participants Michael Okunewithch - Maxim Group James Molloy - Alliance Global Partners Ed Arce - H.C. Wainwright Operator Greetings and welcome to the Acurx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Earnings Results and Business Update Call. At this time, all participan ...

STATEN ISLAND, N.Y., March 18, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the fourth quarter and full year ended December 31, 2023.  Highlights of the fourth quarter ended December 31, 2023, or in some cases shortly thereafter, include: In October 2023, we ended enr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 10-K _____________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40536 Acurx Pharmaceuticals, Inc. (Exact name of Registrant as specified in its Charter) ...

STATEN ISLAND, N.Y., March 4, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its fourth quarter and full year 2023 financial results on Monday, March 18, 2024, at 8:00 am ET before the U.S. financial markets open.David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief ...

As previously announced, planning is underway with FDA to advance ibezapolstat into international Phase 3 clinical trials for treatment of C. difficile Infection (CDI) As anticipated, an End of Phase 2 Meeting (EOP2) with FDA is now confirmed to occur in late April 2024 to finalize the Phase 3 development plan Per FDA Guidance, Acurx also announced it has submitted the required pre-meeting Briefing Document to FDA yesterday, February 26, 2024 SME (Small and Medium-sized Enterprise) designation has been gra ...

NEW YORK, Feb. 02, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street is airing its national TV show on the FOX Business Network on Monday, February 5, 2024, at 10:30 PM. New to The Street's 553rd episode features the following five (5) corporate interviews: 1). Vacation Property Management – The Compass Collection's interviews with Heather Plampin, President/CEO, and Matt Farhat, Head of Business Development. 2). Decentralized Supercomputing – Dynex's (CRYPTO: DNX) ($DNX) interview with Clifford Mapp, ...

NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street TV announces the broadcasting of its business show airing on Bloomberg TV as sponsored programming tonight, Thursday, February 1, 2024, at 9:30 PM PT. New to The Street's TV episode #552 will air the following five (5) business interviews: 1). Biopharmaceutical - Acurx Pharmaceuticals, Inc.'s (NASDAQ:ACXP) ($ACXP) interview with David Luci, President/CEO. 2). Decentralized Supercomputing – Dynex's (CRYPTO: DNX) ($DNX) interview with C ...

In the Phase 2b trial, 100% (5 of 5) of ibezapolstat-treated patients who agreed to observation for up to three months following Clinical Cure of CDI experienced no recurrence of infection Further analyses will be forthcoming as data become available regarding effects on bile acid metabolism and pharmacokinetic data Preparation is underway for meetings with FDA, European Medicines Agency and other global regulatory agencies and advancement to international Phase 3 clinical trials Ibezapolstat has previousl ...

NEW YORK, Jan. 26, 2024 (GLOBE NEWSWIRE) --  FMW Media's New to The Street, a national TV show, announces episode 551, airing on the FOX Business Network on Monday, January 29, 2024, at 10:30 PM PT. New to The Street's 551st episode line-up features the following Five (5) Corporate interviews: 1). Biopharmaceutical -Acurx Pharmaceuticals, Inc.'s (NASDAQ:ACXP) ($ACXP) interview with David Luci, President/CEO. 2). Financial Marketplace Strategies – Blue Castle Ventures LTD's ($BCVD) interviews with David Roja ...

STATEN ISLAND, N.Y., Jan. 23, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company") (NASDAQ: "ACXP"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that David P. Luci, President & Chief Executive Officer, will be presenting at The Microcap Conference, which will take place January 30, 2024-February 1, 2024 at the Ceasars Atlantic City Hotel & Casino in Atlantic City, New Jersey. P ...